.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKinsey
Teva
AstraZeneca
US Department of Justice
Moodys
Baxter
Cerilliant
Argus Health
Harvard Business School

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208159

« Back to Dashboard
NDA 208159 describes VISTOGARD, which is a drug marketed by Wellstat Therap and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the VISTOGARD profile page.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for 208159

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3
Formulation / Manufacturing:see details

Pharmacology for NDA: 208159

Suppliers and Packaging for NDA: 208159

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VISTOGARD
uridine triacetate
GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 69468-151-04 4 PACKET in 1 CARTON (69468-151-04) > 10 g in 1 PACKET (69468-151-10)
VISTOGARD
uridine triacetate
GRANULE;ORAL 208159 NDA Wellstat Therapeutics Corporation 69468-151 69468-151-10 10 g in 1 PACKET (69468-151-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrength10GM/PACKET
Approval Date:Dec 11, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Sep 4, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Dec 11, 2018
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Dec 11, 2022
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY

Expired Orange Book Patents for NDA: 208159

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wellstat Therap
VISTOGARD
uridine triacetate
GRANULE;ORAL208159-001Dec 11, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Fuji
Colorcon
Novartis
Chinese Patent Office
QuintilesIMS
AstraZeneca
Merck
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot